[1] Strehle EM.Long-term management of children with neuromuscular disorders[J]. J Pediatr, 2009, 85(5): 379-384.
[2] Bérard C, Payan C, Fermanian J, et al.A motor function measurement scale for neuromuscular diseases–description and validation study[J]. Rev Neurol (Paris), 2006, 162(4): 485-493.
[3] Sáez A, Acha B, Montero-Sánchez A, et al.Neuromuscular disease classification system[J]. Biomedical Optics, 2013, 18(6): 066017.
[4] 张昊,周宁,吴士文. Duchenne型肌营养不良患者运动功能分析[J]. 中国康复理论与实践, 2018, 24(2): 214-218.
[5] 史惟. Duchenne型肌营养不良症运动功能评价及其临床应用研究进展[J]. 中国现代神经疾病杂志, 2015, 15(6): 426-430.
[6] Vuillerot C, Payan C, Girardot F, et al.Responsiveness of the motor function measure in neuromuscular diseases[J]. Arch Phys Med Rehabil, 2012, 93(12): 2251-2256.
[7] Allard L, Rode G, Jacquin-Courtois S, et al.The motor function measure to study limitation of activity in children and adults with Charcot-Marie-Tooth disease[J]. Ann Phys Rehabil Med, 2014, 57(9-10): 587-599.
[8] Vuillerot C, Payan C, Iwaz J, et al.Responsiveness of the motor function measure in patients with spinal muscular atrophy[J]. Arch Phys Med Rehabil, 2013, 94(8): 1555-1561.
[9] 史惟,李惠,李西华. 复旦中文版神经肌肉疾病运动功能评估量表在儿童和青少年中的信度和效度研究[J]. 中国循证儿科杂志, 2018, 13(1): 35-39.
[10] İnal HS, Tarakç E, Tarakç D, et al.Turkish version of the Motor Function Measure Scale (MFM-32) for neuromuscular diseases: a cross-cultural adaptation, reliability, and validity study[J]. Turk J Med Sci, 2017, 47(6): 1826-1833.
[11] de Lattre C, Payan C, Vuillerot C, et al. Motor function measure: validation of a short form for young children with neuromuscular diseases[J]. Arch Phys Med Rehabil, 2013, 94(11): 2218.
[12] Vuillerot C, Rippert P, Roche S, et al.Development and validation of a motor function classification in patients with neuromuscular disease: The NM-Score[J]. Ann Phys Rehabil Med, 2013, 56(9): 673-686.
[13] Vuillerot C, Meilleur KG, Jain M, et al.English cross-cultural translation and validation of the neuromuscular score: a system for motor function classification in patients with neuromuscular diseases[J]. Arch Phys Med Rehabil, 2014, 95(11): 2064-2070.
[14] Scott E, Eagle M, Mayhew A, et al.Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy[J]. Physiother Res Int, 2012, 17(2): 101-109.
[15] Mazzone ES, Martinelli D, Berardinelli A, et al.North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy[J]. Neuromuscul Disord, 2010, 20(11): 712-716.
[16] Mazzone ES, Messina S, Vasco G, et al.Reliability of the North Star Ambulatory Assessment in a multicentric setting[J]. Neuromuscul Disord, 2009, 19(7): 458-461.
[17] 史惟,李惠,李西华,等. 中文版北极星移动评价量表在Duchenne型肌营养不良症患儿的信度和效度研究[J]. 中国循证儿科杂志, 2017, 12(4): 246-250.
[18] Okama LO, Zampieri LM, Ramos CL, et al.Reliability and validity analyses of the North Star Ambulatory Assessment in Brazilian Portuguese[J]. Neuromuscul Disord, 2017, 27(8): 723-729.
[19] Mayhew A, Cano S, Scott E, et al.Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy[J]. Dev Med Child Neurol, 2011, 53(6): 535-542.
[20] de Sanctis R, Pane M, Sivo S, et al. Suitability of North Star Ambulatory Assessment in young boys with Duchenne muscular dystrophy[J]. Neuromuscul Disord, 2015, 25(1): 14-18.
[21] Ramsey D, Scoto M, Mayhew A, et al.Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool[J]. PLoS One, 2017, 12(2): e0172346.
[22] Mercuri E, Coratti G, Messina S, et al.Revised North Star Ambulatory Assessment for young boys with Duchenne muscular dystrophy[J]. PLoS One, 2016, 11(8): e0160195.
[23] Main M, Kairon H, Mercuri E, et al.The Hammersmith Functional Motor Scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation[J]. Eur J Paediatr Neurol, 2003,7(4): 155-159.
[24] Mercuri E, Messina S, Battini R, et al.Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study[J]. Neuromuscul Disord, 2006, 16(2): 93-98.
[25] Mazzone E, de Sanctis R, Fanelli L, et al. Hammersmith Functional Motor Scale and Motor Function Measure-20 in nonambulant SMA patients[J]. Neuromuscul Disord, 2014, 24(4): 347-352.
[26] Krosschell KJ, Maczulski JA, Crawford TO, et al.A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy[J]. Neuromuscul Disord, 2006, 16(7): 417-426.
[27] Krosschell KJ, Scott CB, Maczulski JA, et al.Reliability of the Modified Hammersmith Functional Motor Scale in young children with spinal muscular atrophy[J]. Muscle Nerve, 2011, 44(2): 246-251.
[28] O'Hagen JM, Glanzman AM, McDermott MP, et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients[J]. Neuromuscul Disord, 2007, 17(9): 693-697.
[29] Glanzman AM, O'Hagen JM, McDermott MP, et al. Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III[J]. Child Neurol, 2011, 26(12): 1499-1507.
[30] Glanzman AM, Mazzone E, Main M, et al.The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliability[J]. Neuromuscul Disord, 2010, 20(3): 155-161.
[31] Finkel RS, Hynan LS, Glanzman AM, et al.The test of infant motor performance: reliability in spinal muscular atrophy type I[J]. Pediatr Phys Ther, 2008, 20(3): 242-246.
[32] Finkel RS, Chiriboga CA, Vajsar J, et al.Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study[J]. Lancet, 2016, 388(10063): 3017-3026.
[33] Mendell JR, Al-Zaidy S, Shell R, et al.Single-dose gene-replacement therapy for spinal muscular atrophy[J]. N Engl J Med, 2017, 377(2): 1713-1722.
[34] Mayhew A, Mazzone ES, Eagle M, et al.Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy[J]. Dev Med Child Neurol, 2013, 55(11): 1038.
[35] Pane M, Mazzone ES, Fanelli L, et al.Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy[J]. Neuromuscul Disord, 2014, 24(3): 201-206.
[36] Pane M, Mazzone E, Sivo S, et al.The 6 Minute Walk Test and Performance of Upper Limb in ambulant Duchenne muscular dystrophy boys[J]. PLoS Curr, 2014, 7(1): 1-5.
[37] Pane M, Fanelli L, Mazzone E, et al.Benefits of glucocorticoids in non-ambulant boys/men with Duchennemuscular dystrophy: A multi-centric longitudinal study using the Performance of Upper Limb test[J]. Neuromuscul Disord, 2015, 25(10): 749-753.
[38] Mazzone E, Bianco F, Martinelli D, et al.Assessing upper limb function in non-ambulant SMA patients: development of a new module[J]. Neuromuscul Disord, 2011, 21(6): 406-412.
[39] Sivo S, Mazzone E, Antonaci L, et al.Upper limb module in non-ambulant patients with spinal muscular atrophy: 12 month changes[J]. Neuromuscul Disord, 2015, 25(3): 212-215.
[40] Mazzone ES, Mayhew A, Montes J, et al.Revised upper limb module for spinal muscular atrophy: Development of a new module: RULM in SMA[J]. Muscle Nerve, 2017, 55(6): 869-874.
